Clinical Trial Update: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of ixazomib in relapsed or refractory acute myeloid leukemia has been terminated; results were posted previously.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Del
• Acute Myeloid Leukemia with Inv
• Erythroleukemia
• Megakaryoblastic Leukemia
• Minimally Differentiated Myeloid Leukemia
• Monoblastic Leukemia
• Monocytic Leukemia
• Myeloblastic Leukemia Without Maturation
• Myeloblastic Leukemia with Maturation
• Myelomonocytic Leukemia
• Pure Erythroid Leukemia

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Steven E. Coutre | Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Status: TERMINATED | Results posted: 2017-03-10